Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Baxter
Dow
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR FUNGIZONE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Fungizone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002019 ↗ Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed Liposome N/A 1969-12-31 To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.
NCT00750737 ↗ Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed Enzon Pharmaceuticals, Inc. Phase 3 2008-06-01 The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant. Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis. Secondary objective will be to compare the cost effectiveness of these two prophylactic regimens.
NCT00750737 ↗ Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed M.D. Anderson Cancer Center Phase 3 2008-06-01 The objective of this study is to compare the safety and efficacy of ABLC versus oral Posaconazole in the prevention of invasive fungal infections in high risk patients with hematologic malignancies or hematopoietic stem cell transplant. Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal infections associated with ABLC or Posaconazole prophylaxis. Secondary objective will be to compare the cost effectiveness of these two prophylactic regimens.
NCT00815516 ↗ Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis Terminated Astellas Pharma Global Development, Inc. Phase 3 2013-02-01 The study will evaluate how effective and how safe the drug micafungin is when compared to the drug amphotericin B deoxycholate in treating neonates and young infants with certain fungal infections.
NCT00885703 ↗ High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1/Phase 2 2010-04-16 Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans. CM most often affects people with compromised immune systems, like those with advanced HIV infection. This study explored the safety, tolerability, and therapeutic effect of a new treatment regimen with high-dose fluconazole for management of CM in HIV-infected patients.
NCT01032187 ↗ Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed Ministry of Health, Brazil Phase 4 2007-10-01 The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for this disease in Brazil.
NCT01032187 ↗ Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed University of Brasilia Phase 4 2007-10-01 The purpose of this study is to determine if amphotericin B is effective against visceral leishmaniasis in Brazilian children. Amphotericin B will be compared to meglumine antimoniate which is the current approved drug used for this disease in Brazil.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fungizone

Condition Name

Condition Name for Fungizone
Intervention Trials
HIV Infections 2
Visceral Leishmaniasis 2
Hematologic Malignancies 1
Invasive Fungal Infections 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fungizone
Intervention Trials
Leishmaniasis, Visceral 2
Leishmaniasis 2
Meningitis, Cryptococcal 2
Meningitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fungizone

Trials by Country

Trials by Country for Fungizone
Location Trials
United States 17
Brazil 7
Kenya 2
Canada 2
South Africa 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fungizone
Location Trials
California 3
Texas 2
New Jersey 2
Connecticut 1
Virginia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fungizone

Clinical Trial Phase

Clinical Trial Phase for Fungizone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fungizone
Clinical Trial Phase Trials
Completed 6
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fungizone

Sponsor Name

Sponsor Name for Fungizone
Sponsor Trials
Ministry of Health, Brazil 2
University of Brasilia 2
Liposome 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fungizone
Sponsor Trials
Other 10
Industry 4
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Dow
Moodys
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.